Sunday 18 October 2026
Export BNTC’s income statement to Excel — free account
Benitec Biopharma Limited
BNTC Healthcare Biotechnology
In the quarter to June 2026, EPS fell 11.3%, free cash flow grew 38.9% and total debt fell 46.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
8.11
0.35
−4.14%
Follow BNTC
| Jun '20 | Jan '21 | Jun '21 | Jan '22 | Jun '22 | Jan '23 | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | — | 3 | — | 3 | — | 3 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z-Score |
(15.42) | — | (1.54) | — | (42.32) | — | (66.02) | — | — | — |
P/S ratio |
0.40 | 299.04 | 309.21 | 771.78 | 126.39 | 55.52 | 75.03 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(24.17) | — | (2.86) | — | (97.55) | — | (151.65) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Beneish M-Score |
2.70 | — | — | — | (5.39) | — | 11.02 | — | — | — |
P/Operating CF |
(0.01) | (4.32) | (3.54) | (6.69) | (1.95) | (0.83) | (1.37) | — | — | — |
P/B ratio |
0.00 | 0.98 | 0.91 | 2.07 | 3.29 | 0.54 | 27.86 | — | — | — |
Price to Tangible BV |
0.00 | 0.98 | 0.91 | 2.07 | 3.29 | 0.54 | 27.86 | — | — | — |
EV/Sales |
(93.60) | 9.42 | (25.20) | 370.71 | 79.50 | (60.90) | 45.62 | — | — | — |
EV/EBITDA |
1.18 | 0.00 | 0.11 | 0.00 | 0.00 | 0.29 | 0.00 | — | — | — |
EV/Operating CF |
1.27 | (0.05) | 0.12 | (0.73) | (0.37) | 0.29 | (0.19) | — | — | — |
EV/FCF |
1.25 | (0.04) | 0.11 | (0.72) | (0.37) | 0.29 | (0.19) | — | — | — |
Quick Ratio |
8.68 | 14.46 | 14.47 | 1.61 | 1.61 | 0.64 | 0.64 | 10.39 | 54.32 | 33.70 |
Current Ratio |
9.52 | 15.05 | 15.05 | 1.90 | 1.90 | 0.94 | 0.94 | 10.49 | 54.67 | 34.00 |
Net Debt/EBITDA |
1.19 | 1.50 | 1.48 | 0.20 | 0.20 | 0.12 | 0.12 | 2.27 | 2.33 | 3.52 |
Debt/Assets |
1.84% | 0.00% | 0.00% | 9.36% | 9.36% | 6.36% | 6.36% | 0.00% | 0.50% | 0.15% |
Debt/Equity |
0.02 | 0.00 | 0.00 | 0.19 | 0.19 | 1.41 | 1.41 | 0.00 | 0.01 | 0.00 |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.91 | 0.92 | 0.92 | 0.87 | 0.87 | 0.92 | 0.92 | 0.87 | 0.62 | 0.36 |
Capex/Depreciation |
(0.49) | 0.00 | (0.96) | 0.00 | (0.08) | 0.00 | (0.01) | (2.06) | (0.27) | (1.81) |
Interest Coverage |
— | — | (2,266.00) | — | (557.94) | — | (578.21) | — | — | — |
| (61.67%) | 0.00% | (91.79%) | 0.00% | (159.08%) | 0.00% | (1,268.61%) | (94.29%) | (52.46%) | (33.21%) | |
| (53.69%) | 0.00% | (84.22%) | 0.00% | (133.14%) | 0.00% | (374.86%) | (78.94%) | (49.96%) | (32.28%) | |
ROIC |
(796.25%) | 0.00% | (3,759.96%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(82.35%) | (70.05%) | (70.78%) | (554.95%) | (725.42%) | (5,374.18%) | 12,075.31% | (47.67%) | (39.15%) | (25.80%) |
Average Days of Receivables |
211.13 | 154.66 | 154.66 | 15.00 | 15.00 | 267.67 | 267.67 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
2,942.16% | 11,898.31% | 11,898.31% | 15,441.10% | 15,441.10% | 17,032.00% | 17,032.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
5,457.84% | 10,318.64% | 11,037.29% | 8,567.12% | 9,104.11% | 8,001.33% | 8,509.33% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
232.35% | 0.00% | 1,074.58% | 0.00% | 1,191.78% | 0.00% | 602.67% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
234.50 | 0.94 | 1.05 | 0.42 | 0.18 | 1.67 | (0.09) | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
(15,436.61%) | (36,610.47%) | (101.84%) | (4,570.62%) | (10,787.49%) | (964.43%) | (350.95%) | — | — | — |
Free Cash Flow Yield |
(18,911.28%) | (69.94%) | (71.55%) | (66.97%) | (168.37%) | (377.30%) | (318.10%) | — | — | — |
Revenue per Share |
340.00 | 0.20 | 0.23 | 0.13 | 0.15 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(25,116.67) | (42.96) | (50.82) | (27.98) | (33.07) | (10.99) | (13.00) | (1.06) | (0.65) | (0.35) |
Capex per Share |
(313.33) | 0.00 | (0.88) | 0.00 | (0.03) | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(25,430.00) | (42.96) | (51.69) | (27.98) | (33.10) | (10.99) | (13.00) | (1.07) | (0.65) | (0.36) |
Cash per Share |
32,670.00 | 66.18 | 78.35 | 7.17 | 8.48 | 1.52 | 1.80 | 2.77 | 2.70 | 3.87 |
Shareholders Equity per Share |
34,126.67 | 66.98 | 79.25 | 5.07 | 6.00 | 0.12 | 0.15 | 2.57 | 2.69 | 3.80 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
34,126.67 | 66.98 | 79.25 | 5.07 | 6.00 | 0.12 | 0.15 | 2.57 | 2.69 | 3.80 |
Free Cash Flow |
(7.63) | (12.83) | (13.05) | (15.90) | (15.91) | (18.01) | (18.01) | (19.58) | (23.61) | (16.62) |
Working Capital |
9.67 | 19.24 | 19.24 | 2.29 | 2.29 | (0.25) | (0.25) | 46.75 | 96.72 | 176.34 |
Capital Expenditures |
(0.09) | (0.22) | (0.22) | (0.01) | (0.01) | 0.00 | 0.00 | (0.18) | (0.02) | (0.10) |
Net Current Asset Value |
9.46 | 19.24 | 19.24 | 1.73 | 1.73 | (0.53) | (0.53) | 46.71 | 96.22 | 176.08 |
EV/EBIT |
1.14 | 0.00 | 0.11 | 0.00 | 0.00 | 0.29 | 0.00 | — | — | — |
Capex to Sales |
0.92 | 0.00 | 3.75 | 0.00 | 0.18 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.51 | 0.73 | 0.62 | 0.39 | 0.75 | 0.62 | 1.56 | 0.49 | 0.50 | 0.33 |
Cash ROIC |
(37.67%) | (32.26%) | (32.80%) | (211.51%) | (211.68%) | (605.24%) | (605.28%) | (19.95%) | (12.07%) | (4.65%) |
Accounts Receivable Turnover |
0.08 | 0.00 | 1.40 | 0.00 | 5.21 | 0.00 | 2.59 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
(0.11) | 0.00 | 0.15 | 0.00 | 0.01 | 0.15 | 0.00 | (0.03) | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Average Days of Payables |
(1,461.97) | 182.83 | 2,611.38 | 1,711.22 | 76,244.44 | 0.00 | 0.00 | (14,076.16) | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Average Receivables |
1.30 | 0.04 | 0.04 | 0.01 | 0.01 | 0.03 | 0.03 | 0.14 | 0.13 | 0.02 |
Average Payables |
1.62 | 0.51 | 0.81 | 1.38 | 1.38 | 2.56 | 2.56 | 3.70 | 2.59 | 2.66 |
Average Assets |
15.41 | 16.48 | 16.48 | 13.68 | 13.68 | 5.22 | 5.22 | 28.34 | 75.90 | 141.11 |
Average Common Equity |
13.42 | 15.12 | 15.12 | 11.45 | 11.45 | 1.54 | 1.54 | 23.73 | 72.27 | 137.15 |
Columns are period end dates · fundamentals updated 2 Oct 2026